Clene (NASDAQ:CLNN) Major Shareholder Chidozie Ugwumba Sells 4,139 Shares of Stock

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 4,139 shares of the business’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $5.08, for a total transaction of $21,026.12. Following the transaction, the insider owned 589,046 shares in the company, valued at $2,992,353.68. This trade represents a 0.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Wednesday, January 28th, Chidozie Ugwumba sold 8,717 shares of Clene stock. The stock was sold at an average price of $4.91, for a total transaction of $42,800.47.
• On Monday, January 26th, Chidozie Ugwumba sold 6,418 shares of Clene stock. The shares were sold at an average price of $5.02, for a total transaction of $32,218.36.
• On Friday, January 23rd, Chidozie Ugwumba sold 5,556 shares of Clene stock. The stock was sold at an average price of $5.27, for a total transaction of $29,280.12.
• On Thursday, January 22nd, Chidozie Ugwumba sold 12,665 shares of Clene stock. The shares were sold at an average price of $5.32, for a total value of $67,377.80.
• On Wednesday, January 21st, Chidozie Ugwumba sold 12,119 shares of Clene stock. The shares were sold at an average price of $5.05, for a total value of $61,200.95.
• On Tuesday, January 20th, Chidozie Ugwumba sold 12,432 shares of Clene stock. The stock was sold at an average price of $4.80, for a total value of $59,673.60.
• On Friday, January 16th, Chidozie Ugwumba sold 7,923 shares of Clene stock. The stock was sold at an average price of $5.13, for a total value of $40,644.99.
• On Thursday, January 15th, Chidozie Ugwumba sold 12,563 shares of Clene stock. The shares were sold at an average price of $5.10, for a total value of $64,071.30.
• On Wednesday, January 14th, Chidozie Ugwumba sold 19,621 shares of Clene stock. The stock was sold at an average price of $5.12, for a total value of $100,459.52.
• On Tuesday, January 13th, Chidozie Ugwumba sold 26,105 shares of Clene stock. The shares were sold at an average price of $4.89, for a total transaction of $127,653.45.

Clene Trading Down 5.4%

NASDAQ CLNN opened at $4.91 on Thursday. The stock has a market cap of $53.27 million, a PE ratio of -1.45 and a beta of 0.87. Clene Inc. has a 12 month low of $2.28 and a 12 month high of $13.50. The company’s 50-day moving average price is $6.54 and its 200-day moving average price is $6.54.

Clene (NASDAQ:CLNN) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.06 million. As a group, sell-side analysts forecast that Clene Inc. will post -5.19 earnings per share for the current year.

Hedge Funds Weigh In On Clene

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Scoggin Management LP raised its holdings in Clene by 75.1% in the third quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock worth $1,506,000 after purchasing an additional 107,250 shares in the last quarter. Lunt Capital Management Inc. grew its position in shares of Clene by 2.5% in the 3rd quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock worth $315,000 after buying an additional 1,250 shares during the last quarter. Jones Financial Companies Lllp bought a new position in shares of Clene during the 3rd quarter worth approximately $29,000. Finally, Jane Street Group LLC bought a new position in shares of Clene during the 2nd quarter worth approximately $47,000. Hedge funds and other institutional investors own 23.28% of the company’s stock.

Clene News Roundup

Here are the key news stories impacting Clene this week:

• Positive Sentiment: Analysts give a fresh consensus “Moderate Buy” rating, which could support the stock if sentiment or fundamentals improve. Article Title
• Neutral Sentiment: There are conflicting short?interest reports in late January showing “0 shares” on some dates (likely data errors). This creates short?interest data uncertainty for traders relying on up?to?date borrow/cover signals.
• Negative Sentiment: Major shareholder Chidozie Ugwumba sold a total of ~19,274 CLNN shares across Jan. 26–28 (sales of 6,418 @ $5.02, 4,139 @ $5.08 and 8,717 @ $4.91), netting roughly $96k and reducing his stake. Insider selling of this size from a >10% holder often signals near?term selling pressure. SEC filing: SEC Filing
• Negative Sentiment: Short interest jumped earlier in January — as of Jan. 15 there were 752,820 shares short (up 45.7% from Dec. 31), representing ~10.7% of the float and a ~5.5 days?to?cover. Elevated short interest can accelerate downward moves and increase volatility if negative catalysts persist.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. D. Boral Capital restated a “buy” rating and set a $23.00 price objective on shares of Clene in a report on Friday, January 9th. Benchmark restated a “buy” rating on shares of Clene in a research note on Thursday, December 4th. UBS Group reaffirmed a “buy” rating on shares of Clene in a research note on Wednesday, December 3rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Clene in a research report on Friday, January 9th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $32.60.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).